Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herman Goossens

Showing results (11-20 of 485) with videos related to

Pageof 49
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2013
Mass azithromycin distribution and emerging resistance: taking a minimum harms approachSurbhi Malhotra-Kumar, Herman Goossens
International Journal of Antimicrobial Agents|March 12, 2004
Bacteraemia in Europe--antimicrobial susceptibility data from the MYSTIC surveillance programmeSerhat Unal, Robert Masterton, Herman Goossens
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Is there any difference in quality of prescribing between antibacterials and antifungals? Results from the first global point prevalence study (Global PPS) of antimicrobial consumption and resistance from 53 countriesErlangga Yusuf, Ann Versporten, Herman Goossens
The Journal of Antimicrobial Chemotherapy|October 21, 2009
Comment on: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycinNiels Adriaenssens, Herman Goossens, Samuel Coenen, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2007
Comment on: Can mass media campaigns change antimicrobial prescribing? A regional evaluation studySamuel Coenen, Michiel Costers, Herman Goossens
The Lancet. Infectious Diseases|September 26, 2009
Cefepime and mortalityJeroen Mebis, Herman Goossens, Zwi N Berneman
Scandinavian Journal of Infectious Diseases|February 11, 2010
Cefepime and mortality: a real issue?Jeroen Mebis, Herman Goossens, Zwi Nisan Berneman
The Lancet. Infectious Diseases|December 24, 2021
The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendationsHerman Goossens, Lennie Derde, Peter Horby, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 22, 2009
The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006Faranak Ansari, Mats Erntell, Herman Goossens, et al.
International Journal of Antimicrobial Agents|September 3, 2013
Outpatient systemic antimycotic and antifungal use in Europe: new outcome measure provides new insightNiels Adriaenssens, Samuel Coenen, Ann Versporten, et al.
Pageof 49

Showing results (11-20 of 485) with videos related to

Sort By:
Pageof 49
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2013
Mass azithromycin distribution and emerging resistance: taking a minimum harms approachSurbhi Malhotra-Kumar, Herman Goossens
International Journal of Antimicrobial Agents|March 12, 2004
Bacteraemia in Europe--antimicrobial susceptibility data from the MYSTIC surveillance programmeSerhat Unal, Robert Masterton, Herman Goossens
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Is there any difference in quality of prescribing between antibacterials and antifungals? Results from the first global point prevalence study (Global PPS) of antimicrobial consumption and resistance from 53 countriesErlangga Yusuf, Ann Versporten, Herman Goossens
The Journal of Antimicrobial Chemotherapy|October 21, 2009
Comment on: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycinNiels Adriaenssens, Herman Goossens, Samuel Coenen, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2007
Comment on: Can mass media campaigns change antimicrobial prescribing? A regional evaluation studySamuel Coenen, Michiel Costers, Herman Goossens
The Lancet. Infectious Diseases|September 26, 2009
Cefepime and mortalityJeroen Mebis, Herman Goossens, Zwi N Berneman
Scandinavian Journal of Infectious Diseases|February 11, 2010
Cefepime and mortality: a real issue?Jeroen Mebis, Herman Goossens, Zwi Nisan Berneman
The Lancet. Infectious Diseases|December 24, 2021
The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendationsHerman Goossens, Lennie Derde, Peter Horby, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 22, 2009
The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006Faranak Ansari, Mats Erntell, Herman Goossens, et al.
International Journal of Antimicrobial Agents|September 3, 2013
Outpatient systemic antimycotic and antifungal use in Europe: new outcome measure provides new insightNiels Adriaenssens, Samuel Coenen, Ann Versporten, et al.
Pageof 49